## **Definitions**

## **COVID-19 Discontinuing Isolation- Inpatient Definitions**

UNIVERSAL: This guide should be used for all COVID patients regardless of Ministry COVID Levels

Created: April 2020 Modified: February 24, 2022 Last Review: February 24, 2022 Owner: Clinical and Operations Workgroup: IPC, Clinical Care

©2022 Trinity Health - Livonia, MI. Trinity Health Confidential

The definitions in the <u>National Institutes of Health (NIH) COVID-19 Treatment Guidelines\*</u> are one option for defining severity of illness categories. The highest level of illness severity experienced by the patient at any point in their clinical course should be used when determining severity of illness.

**Mild Illness**: Individuals who have any of the various signs and symptoms of COVID 19 (e.g., fever, cough, sore throat, malaise, headache, muscle pain) without shortness of breath, dyspnea, or abnormal chest imaging.

**Moderate Illness**: Individuals who have evidence of lower respiratory disease by clinical assessment or imaging and a saturation of oxygen (SpO2) ≥94% on room air at sea level.

**Severe Illness**: Individuals who have respiratory frequency >30 breaths per minute, SpO2 <94% on room air at sea level (or, for patients with chronic hypoxemia, a decrease from baseline of >3%), ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) <300 mmHg, or lung infiltrates >50%.

Critical Illness: Individuals who have respiratory failure, septic shock, and/or multiple organ dysfunction.

**Immunocompromised:** For the purposes of this guidance, the following definition was created by the CDC to more generally address colleague occupational exposures.


- Some conditions, such as being on chemotherapy for cancer, untreated HIV infection with CD4 T lymphocyte count < 200, combined primary immunodeficiency disorder, and receipt of prednisone >20mg/day for more than 14 days, may cause a higher degree of immunocompromise and require actions such as lengthening the duration of colleague work restrictions.
- Other factors, such as advanced age, diabetes mellitus, or end-stage renal disease, may pose a much lower degree of immunocompromise and not clearly affect occupational health actions to prevent disease transmission.

## COVID-19 Discontinuing Isolation Inpatient Symptom/Time-Based Strategies

UNIVERSAL: This guide should be used for all COVID patients regardless of Ministry COVID Levels

Created: April 2020 Modified: February 24, 2022 Last Review: February 24, 2022 Owner: Clinical and Operations Workgroup: IPC, Clinical Care

©2022 Trinity Health - Livonia, MI. Trinity Health Confidential



<sup>&</sup>lt;sup>1</sup> A limited number of persons with severe or critical illness, or those who are immunocompromised may produce replication-competent virus beyond 10 days that may warrant extending duration of isolation and precautions for up to 20 days after symptom onset; consider consultation with infection control experts. Follow Local/State Specific guidance if it exceeds the minimum of 10 days. For severely immunocompromised patients (e.g., patients with chronic lymphocytic lymphocytic leukemia and acquired hypogammaglobulinemia, lymphoma and immunochemotherapy, hematopoietic stem-cell transplant, chimeric antigen receptor T-cell therapy, or AIDS) beyond 20 days, a consultation with an infection control expert or infectious disease specialist is recommended prior to discontinuing isolation.

https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html, Retrieved October 6, 2021

Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants" van Kempen, JJA, et.al.

<sup>&</sup>lt;sup>2</sup> Loss of taste and smell may persist for weeks or months after recovery and need not delay the end of isolation

## **COVID-19 Discontinuing Inpatient Isolation; Test-based Method**

UNIVERSAL: This guide should be used for all COVID patients regardless of Ministry COVID Levels

Created: April 2020 Modified: February 24, 2022 Last Review: February 24, 2022 Owner: Clinical and Operations Workgroup: IPC, Clinical Care

